mHag peptide-loaded host dendritic cells

mHag peptide-loaded host dendritic cells are a form of adoptive cell immunotherapy in which host-derived dendritic cells are ex vivo loaded (pulsed) with minor histocompatibility antigen (mHag) peptides and then reintroduced into the patient. Dendritic cells function as professional antigen-presenting cells; when loaded with mHag peptides and administered, they present these specific peptides in the context of major histocompatibility complex (MHC) molecules to T lymphocytes, promoting a targeted immune response—typically CD8+ or CD4+ T cell activation—against cells expressing the relevant mHag antigens. This approach is under investigation for the treatment of diseases such as hematological malignancies post-allogeneic stem cell transplantation, with the goal of inducing graft-versus-leukemia or tumor immunity without eliciting graft-versus-host disease. The mechanism of action centers on antigen presentation via loaded MHC class I and/or class II molecules on dendritic cells, leading to T cell priming and activation. This therapy is considered a personalized cell therapy and is typically manufactured in specialized academic or research centers, sometimes customized for patient-specific antigens[2][6].